Leerink Partners Maintained a Buy on Merck & Co (MRK)

Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On August 26, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $107.

The analyst noted promising clinical trial results as one of the key reasons behind the bullish sentiment. Graybosch noted HARMONi-A, which showed that combining ivonescimab with chemotherapy significantly improved overall survival compared to chemotherapy alone. The analyst believes that this highlights the potential of VEGF-A/PD-(L)1 drug class in treating some lung cancers.

Moreover, ivonescimab offers durable benefits through VEGF-A antagonism. This is important because, unlike similar drugs like bevacizumab, it may avoid common side effects, making it a better option.

Merck & Co., Inc. (NYSE:MRK) is a global health care company that develops and sells prescription medicines, vaccines, and animal health products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.